Savings Experiment: Snow Removal
The Money Man Behind Rick Santorum: Who Is Foster S. Friess?
Dividend Yield: 14.2%
Market Cap: $850 million
You would never expect a small-cap biotech firm to have a monster dividend yield, but PDL Biopharma (PDLI) is a delightful exception.
The company engages in the management of "antibody humanization patents," as well as royalty assets and license agreements with various biotechnology and pharmaceutical firms. In a nutshell, the process of "humanization" helps makes medications compatible with the biology of men and women so that they work properly.
Since PDL doesn't do research of its own and mainly is a cash-rich intermediary for patents, it has plenty of cash to pay some monster dividends.
At the time of this writing, the author did not own shares of PDLI.
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
